Last reviewed · How we verify
NCT07016464
A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.
Phase 1 trial testing REM0045392 in Healthy in 19 participants. Terminated before completion.
23 June 2025
Quick facts
| Lead sponsor | reMYND |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 20 March 2025 |
| Primary completion | 23 June 2025 |
| Estimated completion | 23 June 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- REM0045392 — full drug profile →
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
reMYND — full company profile →
Who can join
Adults 18 to 85, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is testing if the medicine REM0045392 is safe and well-tolerated. It also looks at whether food affects how the medicine works. The medicine will be tested in Healthy men (Part 1 and 2) and Healthy Older men and women (Part 3). Participants will take the medicine once (in Part 1) or during 14 days (in Part 2 and 3), with increasing doses. REM0045392 is being developed as a treatment for Alzheimer's disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Alzheimer's disease drug development pipeline: 2026.
Cummings JL, Zhou Y, Yang Y, Zhong K, et al · · 2026 · PMID 42095064 · DOI 10.1002/trc2.70251
Verify or expand the search:
- PubMed search for NCT07016464
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other reMYND trials
Trials by the same sponsor.
- NCT05478031 — A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease · Phase 2 · terminated
- NCT04672135 — A Phase 1 (First in Human) Randomized, Double-blind, Placebo-controlled SAD, MAD Study With Oral REM0046127 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07016464 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by reMYND
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07016464.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing